Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
Mochida Pharmaceutical plans to file a biosimilar of the humanized anti-human IL-6 receptor monoclonal antibody Actemra (tocilizumab) in Japan, the company revealed on January 15, although it stopped short of providing the specific timeline. In a release posted the same…
To read the full story
Related Article
- Mochida Files Actemra Biosimilar in Japan
March 27, 2025
BUSINESS
- Tanabe to Wind Down NeuroDerm, Scrap EU Launch of Parkinson’s Drug
November 19, 2026
- Shionogi Narrows R&D Pipeline to 21 Priority Programs Across 3 Disease Areas
November 19, 2026
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026





